肝动脉化疗栓塞与B超引导射频消融序贯联合治疗中小肝癌的效果观察

Observation of effect of transcatheter arterial chemoembolization combined with Ultrasound B guided radiofrequency ablation in the treatment of small hepatocellular carcinoma

目的观察中小肝癌行肝动脉化疗栓塞与B超引导射频消融序贯联合治疗的效果。方法选取我院2012年1月~2014年1月收治的80例中小肝癌患者,依据治疗方法将其分为肝动脉化疗栓塞与B超引导射频消融序贯联合治疗组(联合治疗组,n=40)和肝动脉化疗栓塞单独治疗组(单独治疗组,n=40)两组,对两组患者的临床疗效、1年、2年、3年生存情况及复发情况进行统计分析。结果联合治疗组患者的总缓解率92.5%(37/40)显著高于单独治疗组70.0%(28/40)(P<0.05),1年、2年、3年生存率97.5%(39/40)、95.0%(38/40)、87.5%(35/40)均显著高于单独治疗组90.0%(36/40)、82.5%(33/40)、80.0%(32/40)(P<0.05),复发率2.5%(1/40)显著低于单独治疗组17.5%(7/40)(P<0.05)。结论中小肝癌行肝动脉化疗栓塞与B超引导射频消融序贯联合治疗的效果较肝动脉化疗栓塞单独治疗好。

Objective To observe the effect of transcatheter arterial chemoembolization combined with Ultrasound B guided radiofrequency ablation in the treatment of small hepatocellular carcinoma. Methods 80 cases of patients with small hepatocellular carcinoma in our hospital from January 2012 to January 2014 were selected, these patients were divided into transcatheter arterial chemoembolization combined with Ultrasound B guided radiofrequency ablation treat- ment group（combined treatment group, n=40） and transcatheter arterial ehemoembolization alone treatment group （single treatment group, n=40） two groups according to the treatment methods, the effects, 1 year, 2 years, 3 years survival and recurrences of the two groups were statistically analyzed. Results The total remission rate of the combined treatment group 92.5% （37/40） was significantly higher than the single treatment group 70% （28/40） （P〈0.05）, the 1 year, 2 years, 3 years survival rates 97.5% （39/40）, 95.0% （38/40）, 87.5% （35/40） were significantly higher than the single treatment group 90.0% （36/40）, 82.5% （33/40）, 80.0% （32/40） （P〈0.05）, the recurrence rate 2.5% （1/40） was significantly lower than the single treatment group 17.5% （7/40） （P〈0.05）. Conclusion The effect of transcatheter arterial chemoemboliza- tion combined with Ultrasound B guided radiofrequency ablation is better in the treatment of small hepatocellular carci- noma than transcatheter arterial ehemoembolization alone treatment.